Pregled bibliografske jedinice broj: 1260298
BPC157 as Potential Agent Rescuing from Cancer Cachexia
BPC157 as Potential Agent Rescuing from Cancer Cachexia // Current Pharmaceutical Design, 24 (2018), 18; 1947-1956 doi:10.2174/1381612824666180614082950 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1260298 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
BPC157 as Potential Agent Rescuing from Cancer
Cachexia
Autori
Kang, Eun A. ; Han, Young-Min ; An, Jeong Min ; Park, Yong Jin ; Sikiric, Predrag ; Kim, Deok Hwan ; Kwon, Kwang An ; Kim, Yoon Jae ; Yang, Donghwa ; Tchah, Hann ; Hahm, Ki Baik
Izvornik
Current Pharmaceutical Design (1381-6128) 24
(2018), 18;
1947-1956
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
BPC157 ; Cancer cachexia ; cytoprotection ; hypercatabolism ; hypoanabolism ; muscle atrophy
Sažetak
Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system relatedor inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
MZOS-108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Sikirić, Predrag, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Predrag Sikirić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE